Liquid Biopsy Market Trends To Reap Excessive Revenues By 2030

Liquid Biopsy Market Overview:

To a recent research report by Market Research Community, the Liquid Biopsy Market is expected to surpass USD 24.14 Billion by the year 2030, from USD 7.60 Billion in 2021.

A liquid biopsy Market is a non-invasive test that analyzes blood or other bodily fluids to detect cancer or other diseases. It can be used to diagnose, monitor, and potentially treat cancer by detecting cancer-specific DNA or other biomarkers in the blood.

The exosomes/microvesicles segment of the liquid biopsy market is expected to grow at the highest CAGR during the forecast period. This can be attributed to several factors, including the increasing adoption of exosomes as a liquid biopsy in oncology clinical diagnosis, as well as the introduction of novel products that are able to detect and analyze exosomes and microvesicles more effectively.

The Asia-Pacific region is expected to experience the highest growth rate in the liquid biopsy market during the forecast period. This is largely due to the increasing healthcare spending and rising per capita income in countries such as China and India, as well as the ongoing efforts to improve healthcare infrastructure in the region.

Get Sample Report Here: https://marketresearchcommunity.com/sample-request/?rid=662

The Liquid Biopsy Market is projected to grow at a significant pace reaching a CAGR of approximately 13.7%, over the forecast period of 2022–2030, despite a considerable fall in Product sales during the initial phase of pandemic spread and lockdown restrictions imposed globally.

The study is consolidated into major segments and further into sub-segments, such as by technology (multi-gene-parallel analysis (NGS), single gene analysis (PCR microarrays), sample type (blood sample-based, others) biomarker (circulating nucleic acids, CTC, exosomes/microvesicles, circulating proteins) to forecast the market size by value.

Key segments

By technology

· multi-gene-parallel analysis (NGS)

· single gene analysis (PCR microarrays

By sample Type

· blood sample-based

· others

By Biomarker

· circulating nucleic acids

· CTC

· exosomes/microvesicles

· circulating proteins

Lastly, the report includes a regional analysis and country analysis with the latest trends, along with the major key players including Illumina, Inc; Angle plc; Oncimmune; Thermo Fisher Scientific, Inc.; Lucence health Inc.; Freenome holdings, Inc.; Epigenomics AG, QIAGEN; Myriad Genetics, Inc; BIOCEPT, Inc; Guardant Health, Inc; F. Hoffmann-La Roche Ltd.

Contact:

Market Research Community

Email: sales@marketresearchcommunity.com

Contact no.: (US) +1-214-272-0393